Loading...
•
Mar 31, 2022
Akebia Q1 2022 Earnings Report
Akebia reported financial results for Q1 2022 and provided business updates.
Key Takeaways
Akebia Therapeutics reported a total revenue of $61.7 million for the first quarter of 2022, compared to $52.3 million for the first quarter of 2021. Net product revenue was $41.4 million, a 36% increase compared to Q1 2021. The company is focusing on Auryxia commercial success and exploring earlier-stage assets.
Net Auryxia product revenue was $41.4M, a 36% increase over Q1 2021
Akebia is providing net product revenue guidance for Auryxia of $165—$170 million for fiscal year 2022.
Akebia plans to request an end of review meeting with the FDA within ninety days of receipt of the CRL.
Akebia approved a reduction in workforce of approximately 42% across all areas of Akebia.
Revenue by Segment
Forward Guidance
Akebia is providing net product revenue guidance for Auryxia of $165—$170 million for fiscal year 2022. Akebia believes that its cash resources will be sufficient to fund its current operating plan through at least the next twelve months.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...